Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://fayaimr406004.loginblogin.com/51056541/novo-nordisk-s-retatrutide-australia-a-new-hope-for-losing-weight